UDP-glucuronosyltransferase 2B10

BE0009343ProteinHumansUGT2B10

UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile (PubMed:17576790, PubMed:18238858, PubMed:28803208). It is acted on by 10 drugs in DrugBank.

Gene name
UGT2B10
UniProtKB entry
P36537Swiss-Prot
Cellular location
Microsome membrane
Residues / weight
528 residues · 60,773 Da
Also known as
2.4.1.17 · UDPGT 2B10

Resolves to

Protein
UniProtP36537UniProt nameUDB10_HUMAN
Gene
HGNCHGNC:12544NCBI Gene7365GeneCardsUGT2B10
Pharmacology
KEGGhsa:7365
Structure
PDB7YF5
Drugs

What you can answer from here — as of September 07, 2019

10DrugsApproved to experimental, with action, bond type and pharmacological action
Sign in
6Metabolic reactionsDrug transformations it catalyses, substrate to product
Sign in
5GO termsFunction, process and component, as structured annotations
Sign in
1Pfam domainDomain architecture mapped to Pfam families and clans
Sign in
18+ReferencesStructured and connected to the statements they support
Sign in

Which approved drugs act on UDP-glucuronosyltransferase 2B10, how selective are they, and which programs against it are still in active trials?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In